Mid-cap bid target

(Full access for Lifetime Members only)

Mid-cap bid target

28 March 2024

Boring products can make for fabulous businesses. As the old English saying goes: "Where there is muck, there is brass."

In this case, it is quite literally true. This company deals with sh**.

Yet, it has already attracted multiple potential suitors. More than once was this company in the crosshairs of potential bidders.

By 2026 (or earlier), the business is likely to be sold. Management has been incentivised to put the company in order, and more than one major shareholder will be keen to get an exit.

This is – quite literally – a sitting duck for anyone interested in high-quality European businesses that could attract a takeover bid.

By mid-2026, the share price is likely to trade 100% higher than today. A bid could then come in even a bit higher.

Even just the name of this company is a valuable lead, which is why all further details are exclusively available to Undervalued-Shares.com Lifetime Members.

Not a Lifetime Member yet? Sign up for a Membership - just USD 999/one-off.
Already a Lifetime Member? Log into your account to download the report.

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.